U.S. Stock Insider Trading | Teva Pharmaceuticals disclosed 7 insider transactions on March 5

2026-04-07 01:20:48

On March 5, 2026, Teva Pharmaceutical Industries (TEVA) disclosed seven company insider transaction reports. Executive Francis Richard D sold 412k shares on March 3, 2026.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Trade Price/US$	Total Amount/US$
March 5, 2026	Executive	Hughes Eric A	March 3, 2026	Sold	80.8k	32.36	2.6135 million
March 5, 2026	Executive	Francis Richard D	March 3, 2026	Sold	442.9k	32.36	412k
March 5, 2026	Executive	Daniell Richard	March 3, 2026	Sold	129k	32.36	4.1739 million
March 5, 2026	Executive	Savage Brian	March 3, 2026	Sold	1,274	32.36	41.2k
March 2, 2026	Executive	Kalif Eliyahu Sharon	February 26, 2026	Sold	345.8k	33.64	11.6347 million
February 18, 2026	Executive	Francis Richard D	February 15, 2026	Sold	447.8k	34.22	15.3248 million
December 18, 2025	Executive	Weiss Amir	December 16, 2025	Sold	12.3k	30.20	371.5k
December 18, 2025	Director	MIGNONE ROBERTO	December 16, 2025	Sold	77.4k	30.24	2.3406 million
December 11, 2025	Executive	Sabag Mark	December 9, 2025	Bought	118.7k	18.61	2.2095 million
December 11, 2025	Executive	Sabag Mark	December 9, 2025	Sold	98.2k	28.70	2.8177 million

【Company Profile】

Teva Pharmaceutical Industries Limited was incorporated in Israel on February 13, 1944. The company is a global biopharmaceutical business with a major generic drug operation, operating in about 57 markets worldwide. It focuses on innovation in neuroscience and immunology, while also offering complex generic drugs, bio-pharmaceuticals, and pharmacy brand products to meet patients’ needs.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes